These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3859413)

  • 1. Detection of minimal residual disease in acute leukemia: possibilities and limitations.
    Hagenbeek A; Martens AC
    Eur J Cancer Clin Oncol; 1985 Mar; 21(3):389-95. PubMed ID: 3859413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia.
    Martens AC; Hagenbeek A
    Cytometry; 1985 Jul; 6(4):342-7. PubMed ID: 3860369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells.
    Martens AC; Johnson RJ; Kaizer H; Hagenbeek A
    Exp Hematol; 1984 Sep; 12(8):667-71. PubMed ID: 6386506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML).
    Martens AC; van Bekkum DW; Hagenbeek A
    Int J Cell Cloning; 1990 Jan; 8(1):27-38. PubMed ID: 2403582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).
    Martens AC; Van Bekkum DW; Hagenbeek A
    Leukemia; 1990 Apr; 4(4):241-57. PubMed ID: 2195239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease in acute leukaemia: preclinical studies in a relevant rat model (BNML).
    Hagenbeek A; Martens AC
    Baillieres Clin Haematol; 1991 Jul; 4(3):609-35. PubMed ID: 1958883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease.
    Martens AC; Schultz FW; Hagenbeek A
    Blood; 1987 Oct; 70(4):1073-8. PubMed ID: 3477296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model.
    Hagenbeek A; Martens AC
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):763-9. PubMed ID: 6759141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease in leukemia: state of the art 1991.
    Hagenbeek A
    Leukemia; 1992; 6 Suppl 2():12-6. PubMed ID: 1578911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Minimum residual leukemic cells in genetically marked brown Norway rat myelocytic leukemia model].
    Yan Y; Martens AC; Van Bekkum DW
    Zhonghua Zhong Liu Za Zhi; 1992 Nov; 14(6):414-7. PubMed ID: 1304472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
    Wisniewski D; Strife A; Arlin Z; Knowles R; Lambek C; Gulati S; McHendry B; McKenzie S; Clarkson B
    Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotyping of acute myelocytic leukemia (AML) progenitors: an approach for tracing minimal numbers of AML cells among normal bone marrow.
    Delwel R; van Gurp R; Bot F; Touw I; Löwenberg B
    Leukemia; 1988 Dec; 2(12):814-9. PubMed ID: 3199876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
    el-Beltagi HM; Martens AC; Dahab GM; Hagenbeek A
    Leukemia; 1993 Nov; 7(11):1795-800. PubMed ID: 8231248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML).
    Hagenbeek A; Martens AC
    Leuk Res; 1983; 7(4):547-55. PubMed ID: 6578394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unique antigen expressed on myeloid cells and acute leukemia blast cells defined by a monoclonal antibody.
    Ball ED; Graziano RF; Fanger MW
    J Immunol; 1983 Jun; 130(6):2937-41. PubMed ID: 6574189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia.
    Martens AC; de Groot CJ; Hagenbeek A
    Eur J Cancer; 1991; 27(2):161-6. PubMed ID: 1827281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined flow cytometric assessment of cell surface antigens and nuclear TdT for the detection of minimal residual disease in acute leukaemia.
    Drach J; Gattringer C; Huber H
    Br J Haematol; 1991 Jan; 77(1):37-42. PubMed ID: 1998595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of normal hemopoietic stem cells during leukemia growth before and after induction of a complete remission. Studies in a rat model for acute myelocytic leukemia (BNML).
    Martens AC; Hagenbeek A
    Leuk Res; 1987; 11(5):453-9. PubMed ID: 3472017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the clonogenic cell population (Leuk-CFU) in the marrow of BN rats during development of a promyelocytic leukemia (BNML): an in vitro assay.
    Lanotte M; Lacaze N; Gombaud-Saintonge G
    Leuk Res; 1984; 8(1):71-80. PubMed ID: 6583462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease in acute leukemia: lessons learned from animal models.
    Hagenbeck A; Martens AC
    Haematol Blood Transfus; 1990; 33():31-5. PubMed ID: 2323636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.